Form 4: UTHR CEO Exercises, Sells Shares Under 10b5-1 Plan
Insider Trading Report
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised stock options and sold common stock on October 27 and 28, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), engaged in transactions involving the company's common stock on October 27 and 28, 2025.
- On both October 27 and October 28, 2025, Rothblatt exercised 4,000 stock options at an exercise price of $120.26 per share.
- Concurrently, on October 27, 2025, Rothblatt sold a total of 4,000 shares of common stock in multiple trades at weighted average prices ranging from $411.9545 to $420.2887.
- Similarly, on October 28, 2025, Rothblatt sold a total of 4,000 shares of common stock in multiple trades at weighted average prices ranging from $413.5798 to $417.915.
- These transactions were executed pursuant to a pre-arranged 10b5-1 trading plan established on May 2, 2025.
- Following these transactions, Rothblatt directly holds 130 shares of common stock and indirectly holds 643,309 shares through various trusts and spouse.
- The remaining stock options beneficially owned after these transactions total 146,000, with an exercise price of $120.26 and an expiration date of March 15, 2026.
Sentiment
Score: 5
Explanation: A Form 4 filing detailing routine insider transactions under a 10b5-1 plan is generally neutral. It reflects an executive managing their personal equity holdings rather than a direct statement on company performance or future prospects.
Future Outlook
The pre-arranged 10b5-1 trading plan, under which these transactions occurred, is set to continue until either a tranche of 294,000 stock options expiring March 15, 2026, is exhausted, or December 31, 2025, whichever comes first.
Industry Context
This filing is a routine disclosure of insider transactions and does not provide information directly related to broader industry trends or competitive landscape. Such transactions are common for executives managing their equity compensation.
Next Steps
- The pre-arranged 10b5-1 trading plan will continue until the earlier of the exhaustion of 294,000 stock options expiring March 15, 2026, or December 31, 2025.
Key Dates
| Date | Description |
|---|---|
| 03/15/2016 | Date stock options became exercisable. |
| 05/02/2025 | Date the pre-arranged 10b5-1 trading plan was entered into. |
| 10/27/2025 | Date of stock option exercise and common stock sales. |
| 10/28/2025 | Date of stock option exercise and common stock sales. |
| 10/30/2025 | Date the Form 4 was signed. |
| 12/31/2025 | Earliest termination date for the 10b5-1 trading plan. |
| 03/15/2026 | Expiration date for the tranche of stock options and latest termination date for the 10b5-1 trading plan. |
Recommendation
holdThis Form 4 filing details routine insider transactions by the Chairperson & CEO under a pre-arranged 10b5-1 trading plan. Such transactions are typically for personal financial planning and do not inherently signal a change in the company's fundamental outlook or performance. Therefore, it provides no new information to warrant a change in investment recommendation based solely on this filing.
Keywords
United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Share Sale, CEO, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.